ATE143691T1 - Neurotropische wachstumsfaktoren, die ein homeobox-peptid enthalten - Google Patents

Neurotropische wachstumsfaktoren, die ein homeobox-peptid enthalten

Info

Publication number
ATE143691T1
ATE143691T1 AT91910774T AT91910774T ATE143691T1 AT E143691 T1 ATE143691 T1 AT E143691T1 AT 91910774 T AT91910774 T AT 91910774T AT 91910774 T AT91910774 T AT 91910774T AT E143691 T1 ATE143691 T1 AT E143691T1
Authority
AT
Austria
Prior art keywords
growth factors
factors containing
homeobox peptide
neurotropic growth
homeobox
Prior art date
Application number
AT91910774T
Other languages
German (de)
English (en)
Inventor
Alain Joliot
Alain Prochiantz
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE143691T1 publication Critical patent/ATE143691T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT91910774T 1990-06-05 1991-06-05 Neurotropische wachstumsfaktoren, die ein homeobox-peptid enthalten ATE143691T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9006912A FR2662698A1 (fr) 1990-06-05 1990-06-05 Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.

Publications (1)

Publication Number Publication Date
ATE143691T1 true ATE143691T1 (de) 1996-10-15

Family

ID=9397246

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91910774T ATE143691T1 (de) 1990-06-05 1991-06-05 Neurotropische wachstumsfaktoren, die ein homeobox-peptid enthalten

Country Status (9)

Country Link
EP (1) EP0485578B1 (enExample)
JP (1) JP3282130B2 (enExample)
AT (1) ATE143691T1 (enExample)
BR (1) BR9105783A (enExample)
DE (1) DE69122472T2 (enExample)
FR (1) FR2662698A1 (enExample)
IE (1) IE911914A1 (enExample)
PT (1) PT97877A (enExample)
WO (1) WO1991018981A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192312A (en) * 1991-03-05 1993-03-09 Colorado State University Research Foundation Treated tissue for implantation and methods of treatment and use
FR2682875A1 (fr) * 1991-10-24 1993-04-30 Fidia France Sarl Utilisation de l'acide polysialique alpha2-8 pour la regulation de l'action des peptides homeoboites.
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
US5846743A (en) * 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
GB9521544D0 (en) * 1995-10-20 1995-12-20 Univ Dundee Activation of P53 protein and therapeutic applications thereof
US6962792B1 (en) 1996-05-08 2005-11-08 Cyclacel Limited Methods and means for inhibition of Cdk4 activity
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6800286B1 (en) 1998-08-19 2004-10-05 The Regents Of The University Of Colorado Chimeric fibroblast growth factor proteins, nucleic acid molecules, and uses thereof
IL142869A0 (en) 1998-11-13 2002-03-10 Cyclacel Ltd Transport vectors
DE10027777A1 (de) * 2000-06-07 2001-12-13 Otogene Ag Transfektionsverfahren
FR2810046B1 (fr) * 2000-06-07 2004-09-10 Neurotech Procede d'immortalisation conditionnelle de cellules et les constructions proteiques pour sa mise en oeuvre
CA2576159A1 (en) 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
FR2897780B1 (fr) 2006-02-28 2008-05-23 Centre Nat Rech Scient Utilisation de la proteine a homeodomaine engrailed comme anxiolytique
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
CN102459329A (zh) 2009-04-14 2012-05-16 特洛伊科技有限公司 治疗性触角足-抗体分子及其使用方法
GB201507722D0 (en) 2015-05-06 2015-06-17 Norwegian Univ Sci & Tech Ntnu Anti-bacterial agents and their use in therapy
PL3960195T3 (pl) * 2015-09-23 2025-06-09 Centre National De La Recherche Scientifique Engrailed do zastosowania w leczeniu stwardnienia zanikowego bocznego
AU2024207403A1 (en) 2023-01-13 2025-07-24 Brainever Stabilized engrailed protein aqueous compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system

Also Published As

Publication number Publication date
IE911914A1 (en) 1991-12-18
JP3282130B2 (ja) 2002-05-13
DE69122472T2 (de) 1997-04-17
DE69122472D1 (de) 1996-11-07
EP0485578A1 (fr) 1992-05-20
JPH05502885A (ja) 1993-05-20
WO1991018981A2 (fr) 1991-12-12
WO1991018981A3 (fr) 1992-03-19
EP0485578B1 (fr) 1996-10-02
FR2662698A1 (fr) 1991-12-06
FR2662698B1 (enExample) 1995-03-24
BR9105783A (pt) 1992-07-21
PT97877A (pt) 1992-04-30

Similar Documents

Publication Publication Date Title
DE69122472D1 (de) Neurotropische wachstumsfaktoren, die ein homeobox-peptid enthalten
DE3381783D1 (de) Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
DE69605486D1 (de) Sekundärbatterie mit Elektroden die ein mehrphasiges, poröses aktives Material enthalten
DE69019009D1 (de) Zellkulturverfahren.
NO912321D0 (no) Stamcellefaktor.
ITTV930017A0 (it) Struttura di contenitore, particolarmente per le colture cellulari
DE69010097D1 (de) Elektrode für Sekundärbatterie.
DE69016086D1 (de) Verfahren zum Züchten von Zellgewebe.
IT7823792A0 (it) Protesi di valvola cardiaca emetodo per la sua produzione.
FI872457A7 (fi) Elektrolytisk cell.
IT1238539B (it) Cella elettrochimica.
DE68918565D1 (de) Verfahren zur herstellung von sonnenzellenkontakten.
NO900348D0 (no) Hybrid kunststoffmaterialer.
DE3750011D1 (de) Elektrolytlösung für elektrolytkondensator, sowie mit dieser lösung hergestellter elektrolytkondensator.
ES2168276T3 (es) 1-arilsulfonil-3-fenil-1,4,5,6-tetrahidropiridazinas.
DE3788671D1 (de) Kathodische Elektrode.
FI973262A0 (fi) Elektrolyysikennossa käytettävä katodi
FI883527L (fi) Elektrolytisk cell.
IT7828182A0 (it) Elettrolitica. procedimento e cella elettrolitica per la trasformazione elettrochimica di sostanze, che si trovano in una soluzione
DE69015032D1 (de) Elektrochemische Zelle.
DE3852795D1 (de) Elektrochemische Zelle.
FI874921A7 (fi) Elektrolyysikenno.
ATE84548T1 (de) Expression in e.coli von hybridpolypeptiden, die die sequenz des wachstumshormons ausloesenden faktors enthalten.
IT7822620A0 (it) 3,1-s-alfa2-glicoproteina, ricca di leucina, processo per la sua preparazione e suo impiego.
DE3778068D1 (de) Elektrolytische zelle.